Excision BioTherapeutics, Inc. today announced presentation of six abstracts at the ASGCT 2024 Annual Meeting, which is being held from May 7-11, 2024 in Baltimore, Maryland.
- Excision to give three oral presentations and outline new data in three posters from preclinical programs for herpes keratitis (HSV-1 Keratitis) and hepatitis B virus (HBV) as well as a next-generation AAV vector
- Update on the EBT-101 first-in-human trial to be presented in an oral session
SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious latent viral infectious diseases, today announced presentation of six abstracts at the ASGCT 2024 Annual Meeting, which is being held from May 7-11, 2024 in Baltimore, Maryland. The presentations are related to new data for the Company’s emerging preclinical programs for herpes simplex virus-1 keratitis (HSV-1 Keratitis) and hepatitis B virus (HBV), as well as an overview of a next generation AAV delivery vector. In addition, there will be an update on the Company’s first-in-human study of EBT-101.
Presentation details: Oral Presentations
Title:Non-Viral Gene Editing with Dual Guide RNAs for Chronic Hepatitis B Infection
Excision Program: HBV
Session Type: Oral presentation
Session Title: Gene Disruption and Excision
Abstract: 153
Presenter: Ryo Takeuchi, Excision BioTherapeutics
Location: Ballroom 3
Date/Time: May 09, 2024, 2:21 to 2:38 pm (EST)
Title:Selecting highly conserved and specific guide RNAs for CRISPR/CasX-mediated gene editing of the HSV-1 genome
Excision Program: HSV-1 Keratitis
Session Type: Oral presentation
Session Title: On- and Off-target Method Development
Abstract: 256
Presenter: Meltem Isik, Excision BioTherapeutics
Location: Ballroom 3
Date/Time: May 10, 2024, 2:00 to 2:15 pm (EST)
Title:EBT-101: First-in-human clinical trial of systemic CRISPR-CA9 multiplex targeting of Latent HIV
Excision Program: HIV
Session Type: Oral presentation
Location: Ballroom 2
Date/Time: May 10, 2024, 9:18 AM to 9:44 AM (EST)
Presentation details: Poster Presentations
Title:CRISPR/CasX-Mediated Gene Editing as a Therapeutic Approach for HSV-1 Keratitis
Excision Program: HSV-1 Keratitis
Session Type: Poster presentation
Session Title: Gene Disruption and Excision
Abstract: 1188
Presenter: Guoxiang Ruan, Excision BioTherapeutics
Location: Exhibit Hall
Date/Time: May 09, 2024, 5:30 to 7:00 pm (EST)
Title:Develop Next Generation All-in-One AAV Vectors for CRISPR/Cas Gene Editing with Paired Guide RNAs
Excision Program: Next Generation Vectors
Session Type: Poster presentation
Session Title: AAV Vectors – Virology and Vectorology
Abstract: 966
Presenter: Wenwen Huo, Excision BioTherapeutics
Location: Exhibit Hall
Date/Time: May 09, 2024, 5:30 to 7:00 pm (EST)
Title:CRISPR/Cas9-mediated gene editing for herpes simplex virus reduces viral reactivation in a latent rabbit keratitis model
Excision Program: HSV-1 Keratitis
Session Type: Poster presentation
Session Title: Ophthalmic and Auditory Diseases
Abstract: 1633
Presenter: Nadia Amrani, Excision BioTherapeutics
Location: Exhibit Hall
Date/Time: May 10, 2024, 5:30 to 7:00 pm (EST)
About Excision BioTherapeutics, Inc.
Excision BioTherapeutics, Inc. develops CRISPR-based medicines as potential cures for serious viral latent infectious diseases based its proprietary multiplexed gene editing platform that unites next-generation CRISPR nucleases with a novel gene editing approach to develop curative therapies. The Company’s pipeline targets large, underserved markets including herpes simplex virus-1 keratitis (HSV-1 keratitis), hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1). Excision’s foundational technologies were developed in the laboratories of Dr. Kamel Khalili at Temple University and Dr. Jennifer Doudna at the University of California, Berkeley. For more information, please visit www.excision.bio.
Contact:
John Fraunces
LifeSci Advisors
917-355-2395
jfraunces@lifesciadvisors.com
